Tech Company Financing Transactions
Proacta Funding Round
Proacta, based in La Jolla, raised $35 million from Clarus, Alta Partners and Delphi Ventures.
Transaction Overview
Company Name
Announced On
2/7/2007
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series B
Investors
Clarus (Lead Investor) (Dennis Henner)
Delphi Ventures (Deepa Pakianathan)
Proceeds Purpose
The new funding will take Proacta's lead compound, PR-104, through the next phase of clinical development and support the discovery and development of additional compounds.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
4275 Executive Square 440
La Jolla, CA 92037
USA
La Jolla, CA 92037
USA
Phone
Website
Email Address
Overview
Proacta is developing a new generation of cancer drugs that uniquely target physiological attributes of solid tumors.Proacta's first lead program, a hypoxia targeted small-molecule prodrug, is designed to improve the outcomes of current treatment regimens, including chemotherapy and radiotherapy.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Gutheil
Chief Financial Officer
Kevin Torre
Browse more venture capital transactions:
Prev: 2/6/2007: Tango Networks venture capital transaction
Next: 2/7/2007: Maxion Technologies venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to document every notable VC transaction. VC investment data records reported here come from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs